Condition: B-Cell Neoplasm · Sponsor: Miltenyi Biomedicine GmbH
This is a single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric and adolescent subjects (aged between 6 months and \<18 years, ≥6 kg body weight \[BW\]) with mature B-cell neoplasms and aggressive lymphomas that relapsed after or are refractory to one or more prior therapies, including subjects with primary refractory disease.
This description comes directly from the study's public registry record.
Andrey Shirokov · +49 151 1179 4851 · andrey.shirokov@miltenyi.com
Gregor Zadoyan, Dr. · +49 151 4025 8225 · gregor.zadoyan@miltenyi.com
Always discuss trial participation with your own doctor first.
| Hôpital Robert Debré | Paris, Boulevard Sérurier 48, France | Active Not Recruiting |
| Institut Gustave Roussy | Villejuif, France | Recruiting |
| Universitaetsklinikum Muenster (UKM) - Klinik fuer Kinder- und Jugendmedizin - Paediatrische Haematologie und Onkologie | Münster, Albert-Schweitzer-Campus 1, Gebaeude A1, Germany | Active Not Recruiting |
| IRCCS Ospedale Pediatrico Bambino Gesù | Rome, Piazza Sant Onofrio 4, Italy | Recruiting |
| Prinses Maxima Centrum | Utrecht, Heidelberglaan 25, Netherlands | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06508931